Comparative Pharmacology
Head-to-head clinical analysis: FARXIGA versus JARDIANCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FARXIGA versus JARDIANCE.
FARXIGA vs JARDIANCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose.
Sodium-glucose co-transporter 2 (SGLT2) inhibitor; reduces renal glucose reabsorption, lowering blood glucose independent of insulin.
10 mg orally once daily, with or without food.
10 mg orally once daily, may increase to 25 mg orally once daily if tolerated and additional glycemic control needed.
None Documented
None Documented
Terminal elimination half-life 12-13 hours; supports once-daily dosing. Steady-state reached in 5 days.
Terminal elimination half-life is approximately 12.9 hours in healthy subjects. Steady-state is achieved after 4-5 days of once-daily dosing. Effective half-life for accumulation: ~4-6 hours.
Renal (33% as parent, 66% as glucuronide conjugates in urine); fecal (1.5% as parent); biliary (minor).
Primarily renal: approximately 70-80% of absorbed dose excreted unchanged in urine via glomerular filtration and active tubular secretion. Fecal: ~10-20% via biliary and fecal elimination.
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor